Mark Vieth, Senior Vice President at Cavarocchi Ruscio Dennis Associates and the Foundation for Peripheral Neuropathy’s advocacy consultant in Washington, D.C., confirmed that the president and Congressional leaders recently reached an important two-year budget deal, paving the way for the Senate to complete its spending bills in September. As a result, in early September, the […]
Read More… from Call to Action! Help Us Get Your Voice Heard for More Research Funding!
On July 9, 2018, the Federal Drug Administration (FDA) held a public forum focusing on the patient’s perspective on drug development for chronic pain. The FDA invited members of the public, including the Foundation for Peripheral Neuropathy’s (FPN) President, Lou Mazawey, to attend to give their perspectives on living with chronic pain and treatment approaches […]
Read More… from FDA and FPN survey patients on chronic pain and treatments
On December 3, 2015, Astellas Pharma US, Inc. (the U.S. affiliate of Astellas Pharma Inc.), a R&D-driven global pharmaceutical company, invited the Foundation for Peripheral Neuropathy to present to a global team working on development of ASP3662 for patients with neuropathic pain (NP). This was an internal meeting, which included Ulf Tollemar, Executive Director, Development […]